Lin, J., Zhang, C., Yan, L., Yang, X., Dong, S., Jiang, B., Nie, Q., Liao, R., Kang, J., Xu, Z., Zhang, J., Yang, J., Zhang, S., Hou, J., Fu, R., Chen, Z., Qiu, Z., Wu, Y., Zhong, W. (2026). Neoadjuvant almonertinib followed by chemo-immunotherapy in II-IIIb EGFR-mutant NSCLC: A single arm, phase II study (NEOVADE).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8509